References
- Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–32.
- Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–61.
- Baccarani M, Dreyling M; ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v165–7.
- George S, Horvath L, Molokie R, Berry J, Rondelli D, Hoffman R, editors. Response to Therapy with imatinib mesylate in patients with CML is poor in non-caucasian patients. ASH Annual Meeting Abstr; 2004;104:2937.
- Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541–52.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973–2008 varying) – Linked To County Attributes – Total U.S., 1969–2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
- Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941–8.
- Kantarjian HM, Talpaz M, O’Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835–40.
- de Lavallade H, Milojkovic D, Khorashad J, Reid A, Olavarria E, Kaeda J, et al. Outcome, prognostic factors and long-term follow-up in 207 chronic phase CML patients receiving front-line imatinib 400 mg at a single institution. ASH Annual Meeting Abstr 2007;110:1045.
- Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963–6.
- Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 2010;123:764.e1–9.
- Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Haematologica 2008;93:1544–9.
- Thygesen LC, Nielsen OJ, Johansen C. Trends in adult leukemia incidence and survival in Denmark, 1943–2003. Cancer Causes Control 2009;20:1671–80.
- Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, et al. Socioeconomic status and cancer survival. J Clin Oncol 1991;9:1500–9.
- Singh GK, Miller BA, Hankey BF, Edwards BK. Area socioeconomic variations in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975–1999. NCI Cancer Surveillance Monograph Series. Number 4. Bethesda: National Cancer Institute; 2003.